Article
Oncology
Anastasia Prokopi, Christoph H. Tripp, Bart Tummers, Florian Hornsteiner, Sarah Spoeck, Jeremy Chase Crawford, Derek R. Clements, Mirjana Efremova, Katharina Hutter, Lydia Bellmann, Giuseppe Cappellano, Bruno L. Cadilha, Sebastian Kobold, Louis Boon, Daniela Ortner, Zlatko Trajanoski, Suzie Chen, Tanja D. de Gruijl, Juliana Idoyaga, Douglas R. Green, Patrizia Stoitzner
Summary: Immunotherapy with checkpoint inhibitors has shown impressive results in patients with melanoma, but many still do not benefit from this treatment due to factors such as lack of tumor-infiltrating T cells and loss of intratumoral dendritic cells. In a melanoma mouse model, researchers found that tumor progression is characterized by upregulation of checkpoint molecules and gradual loss of dermal conventional DC 2 subset. Monotherapy with checkpoint blockade was not effective, but boosting DC numbers and activation increased tumor immunogenicity, leading to improved T cell function and delayed tumor growth when combined with antibodies against PD-1 and TIM-3. The study highlights the importance of skin DC in cancer immunotherapy and suggests that restoring DC function is key to enhancing tumor immunogenicity and responsiveness to checkpoint blockade therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Hemavathi Dhandapani, Hascitha Jayakumar, Abirami Seetharaman, Shirley Sunder Singh, Selvaluxmy Ganeshrajah, Nirmala Jagadish, Anil Suri, Rajkumar Thangarajan, Priya Ramanathan
Summary: Dendritic cell-based immunotherapy utilizing recombinant human SPAG9 shows promise in stimulating CD4(+) and CD8(+) T cell responses for cervical cancer patients. The study suggests rhSPAG9 as a strong immunogen for DC-based immunotherapy and highlights the potential of a combinatorial regimen with cisplatin for therapeutic intervention.
CANCER CELL INTERNATIONAL
(2021)
Article
Oncology
Yoke Seng Lee, Liam J. O'Brien, Carina M. Walpole, Frances E. Pearson, Ingrid M. Leal-Rojas, Kelly-Anne Masterman, Victoria Atkinson, Andrew Barbour, Kristen J. Radford
Summary: The study found that the number of CD141(+) dendritic cells in the blood of melanoma patients was significantly reduced, and these cells exhibited impaired function after peripheral stimulation. In non-responding patients, the number and function of these cells continued to decline during treatment. Indirectly expanding and activating CD141(+) dendritic cells in vivo with Flt3L and a TLR3 agonist can enhance the efficacy of anti-PD-1 treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Zining Wang, Feifei Xu, Jie Hu, Hongxia Zhang, Lei Cui, Wenhua Lu, Wenzhuo He, Xiaojuan Wang, Mengyun Li, Huanling Zhang, Wenjing Xiong, Chunyuan Xie, Yongxiang Liu, Penghui Zhou, Jinyun Liu, Peng Huang, Xiaofeng Frank Qin, Xiaojun Xia
Summary: Clotrimazole was identified as a drug that could enhance DC-mediated antigen presentation and T cell response, by acting on hexokinase 2 to regulate metabolic production and enhancing the lysosome pathway and Chop expression in DCs. In vivo administration of clotrimazole induced immune infiltration and inhibited tumor growth, synergizing with anti-PD1 antibody therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Xiaowu Bai, Chi Chun Wong, Yasi Pan, Huarong Chen, Weixin Liu, Jianning Zhai, Wei Kang, Yu Shi, Masami Yamamoto, Tetsuya Tsukamoto, Sachiyo Nomura, Philip Chiu, Jun Yu, Enders Kwok-wai Ng
Summary: YTHDF1 is overexpressed in gastric cancer and promotes cancer growth by inducing cell proliferation and suppressing dendritic cell-mediated anti-tumor immune response. YTHDF1 is a promising therapeutic target for gastric cancer treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Biochemistry & Molecular Biology
Jennifer Peil, Felix Bock, Friedemann Kiefer, Rebecca Schmidt, Ludwig M. Heindl, Claus Cursiefen, Simona L. Schlereth
Summary: Conjunctival melanoma is a rare type of ocular melanoma, and current therapies still have issues with recurrence and metastasis. Recent advances in immune checkpoint inhibitors have shown promising results in melanoma treatment, but the immunological background of conjunctival melanoma is not well understood, highlighting the need for further research. Tumor cells exploit inhibitory targets on T-cells, but enhancing immune response through dendritic cells and interfering with lymphatic pathways may provide important therapeutic opportunities for conjunctival melanoma.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Chemistry, Multidisciplinary
Cao Dai Phung, Tuan Hiep Tran, Hanh Thuy Nguyen, Tien Tiep Nguyen, Jee-Heon Jeong, Sae Kwang Ku, Chul Soon Yong, Han-Gon Choi, Jong Oh Kim
Summary: Efforts in developing cancer vaccines have faced challenges, but a new artificial nanovaccine targeting lymphatic dendritic cells shows promise in boosting immune response and controlling immunosuppression simultaneously. By incorporating IL-10 siRNA to inhibit suppressive cytokine secretion and utilizing a CD205 antibody for enhanced dendritic cell targeting, the nanovaccine demonstrates potential for enhancing antitumor immunity.
JOURNAL OF CONTROLLED RELEASE
(2021)
Article
Oncology
Mirela Kremenovic, Alfred A. Chan, Bing Feng, Lukas Baeriswyl, Steve Robatel, Thomas Gruber, Li Tang, Delphine J. Lee, Mirjam Schenk
Summary: In this study, a novel BCG lysate was developed and formulated into a thermosensitive hydrogel. The BCG lysate exhibited enhanced antitumor efficacy and promoted a proinflammatory tumor microenvironment in vivo. The underlying mechanisms of BCG lysate-mediated tumor immunity relied on macrophages (M phi) and dendritic cells (DCs). The BCG hydrogel treatment induced systemic immunity, suppressed lung metastases, and improved survival in melanoma-bearing mice. Furthermore, BCG hydrogel treatment enhanced antigen processing and presentation, and increased the frequency of melanoma-reactive CD8(+) T cells. In human melanoma patients, intralesional-BCG treatment was associated with enhanced M1 M phi, mature DCs, antigen processing and presentation, and increased patient survival.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Biotechnology & Applied Microbiology
Maike Delic, Veronika Boeswald, Katrin Goepfert, Petra Pabst, Markus Moehler
Summary: We studied the immune response against melanoma cells after infection with JS-1 or T-VEC and evaluated their antitumoral efficacy. We found enhanced activation of human cytotoxic T lymphocytes after infection with both viruses, and no significant differences were observed between T-VEC and JS-1 after treatment with cytostatic drugs.
ONCOTARGETS AND THERAPY
(2022)
Review
Immunology
Mahdi Abdoli Shadbad, Khalil Hajiasgharzadeh, Afshin Derakhshani, Nicola Silvestris, Amir Baghbanzadeh, Vito Racanelli, Behzad Baradaran
Summary: Although melanoma remains the deadliest skin cancer, immunotherapy has provided more tolerable approaches and revolutionized cancer therapy. However, the undesirable response rates of traditional approaches and the immunosuppressive tumor microenvironment have raised questions about their clinical translation. Additional research on oncogenic pathways and novel tumor antigens is essential for developing more effective dendritic cell-based vaccines.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Florian Maerkl, Mohamed-Reda Benmebarek, Julius Keyl, Bruno L. Cadilha, Martina Geiger, Clara Karches, Hannah Obeck, Melanie Schwerdtfeger, Stefanos Michaelides, Daria Briukhovetska, Sophia Stock, Jakob Jobst, Philipp Jie Mueller, Lina Majed, Matthias Seifert, Anna-Kristina Kluever, Theo Lorenzini, Ruth Gruenmeier, Moritz Thomas, Adrian Gottschlich, Richard Klaus, Carsten Marr, Michael von Bergwelt-Baildon, Simon Rothenfusser, Mitchell P. Levesque, Markus Vincent Heppt, Stefan Endres, Christian Klein, Sebastian Kobold
Summary: Melanoma is an immune sensitive disease, and immune check point blockade has shown activity. However, TIL therapy after ICB failure has shown promising efficacy, indicating the potential of cellular therapies. To overcome limitations of TIL treatment, a controlled adoptive cell therapy approach using synthetic agonistic receptors and bispecific antibodies targeting melanoma-associated antigens is proposed.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Multidisciplinary Sciences
Giacomo Oliveira, Kari Stromhaug, Susan Klaeger, Tomasz Kula, Dennie T. Frederick, Phuong M. Le, Juliet Forman, Teddy Huang, Shuqiang Li, Wandi Zhang, Qikai Xu, Nicoletta Cieri, Karl R. Clauser, Sachet A. Shukla, Donna Neuberg, Sune Justesen, Gavin MacBeath, Steven A. Carr, Edward F. Fritsch, Nir Hacohen, Moshe Sade-Feldman, Kenneth J. Livak, Genevieve M. Boland, Patrick A. Ott, Derin B. Keskin, Catherine J. Wu
Summary: The authors demonstrate through single-cell profiling and T cell receptor specificity screening that tumour antigen recognition influences the phenotypes of CD8(+) T cells and antitumour immune responses. Non-tumour-reactive T cells show a non-exhausted memory phenotype, while melanoma-reactive lymphocytes exhibit an exhausted state, providing insights into the properties of the anti-melanoma TCR repertoire.
Review
Biochemistry & Molecular Biology
Sara Nava, Daniela Lisini, Simona Frigerio, Anna Bersano
Summary: DCs vaccines have established safety and the ability to induce anti-tumor responses, and combining with other treatments may improve efficacy. Combinatorial approaches of DCs-based immunotherapy with chemotherapy and radiotherapy could be the key to cancer treatment paradigms.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Biochemistry & Molecular Biology
Katerina Kalkusova, Sindija Smite, Elea Darras, Pavla Taborska, Dmitry Stakheev, Luca Vannucci, Jirina Bartunkova, Daniel Smrz
Summary: The immune checkpoint inhibitors are crucial in cancer immunotherapy, but their efficacy is limited in solid tumors. Mast cells and dendritic cells play important roles in the tumor immune microenvironment and controlling these cells may help overcome the resistance of solid tumors to immunotherapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Chemistry, Multidisciplinary
Min Li, Han Zhou, Minghao Fang, Kun Qu, Yucai Wang
Summary: The use of dual-targeting nanomedicines to improve tumor antigen presentation by both dendritic cells (DCs) and tumor cells is proposed as a strategy to enhance antitumor immunity and tumor cell killing.
ADVANCED FUNCTIONAL MATERIALS
(2023)
Article
Respiratory System
Lucile Regard, Clemence Martin, Jean-Luc Teillaud, Helene Lafoeste, Hugues Vicaire, Maha Zohra Ladjemi, Emilie Ollame-Omvane, Sophie Siberil, Pierre-Regis Burgel
Summary: Depletion of B cells and/or T cells led to disorganisation or abolishment of tertiary lymphoid structures (TLS) in mice persistently infected with S. aureus, showing no impact on infection control.
EUROPEAN RESPIRATORY JOURNAL
(2021)
Editorial Material
Medicine, Research & Experimental
Jean-Luc Teillaud
M S-MEDECINE SCIENCES
(2021)
Article
Immunology
Claire Germain, Priyanka Devi-Marulkar, Samantha Knockaert, Jerome Biton, Helene Kaplon, Laila Letaief, Jeremy Goc, Agathe Seguin-Givelet, Dominique Gossot, Nicolas Girard, Pierre Validire, Marine Lefevre, Diane Damotte, Marco Alifano, Francois M. Lemoine, Keith E. Steele, Jean-Luc Teillaud, Scott A. Hammond, Marie-Caroline Dieu-Nosjean
Summary: The presence of high TLS-B cell density in NSCLC tumors is associated with better clinical outcomes and more specific CD4(+) T cell responses. High TLS-B cell density can counterbalance the negative impact of high Treg density on patient survival, suggesting a central role for B cells in determining protective T cell responses in NSCLC patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Charlotte Domblides, Juliette Rochefort, Clemence Riffard, Marylou Panouillot, Geraldine Lescaille, Jean-Luc Teillaud, Veronique Mateo, Marie-Caroline Dieu-Nosjean
Summary: The tumor microenvironment is unique to each patient and therapies targeting tumor cells or immune cells have limited long-term benefits. Hot tumors play a role in selecting therapies targeting patient immunity, with the presence of TLS associated with better survival and predicted response to ICP inhibitors. Increasing understanding of TLS biology may improve prognostic prediction and treatment selection for cancer patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Chemistry, Multidisciplinary
Matthew J. Mosquera, Sungwoong Kim, Rohan Bareja, Zhou Fang, Shuangyi Cai, Heng Pan, Muhammad Asad, Maria Laura Martin, Michael Sigouros, Florencia M. Rowdo, Sarah Ackermann, Jared Capuano, Jacob Bernheim, Cynthia Cheung, Ashley Doane, Nicholas Brady, Richa Singh, David S. Rickman, Varun Prabhu, Joshua E. Allen, Loredana Puca, Ahmet F. Coskun, Mark A. Rubin, Himisha Beltran, Juan Miguel Mosquera, Olivier Elemento, Ankur Singh
Summary: This study defined the role of ECM signals in the development of CRPC-NEPC and identified potential therapeutic targets for neuroendocrine prostate cancer. In animal models, strong anti-tumor responses were observed with the use of a DRD2 inhibitor, and a combination of epigenetic inhibitors and DRD2 treatment was shown to overcome therapeutic resistance in CRPC-NEPC under drug-resistant ECM conditions.
ADVANCED MATERIALS
(2022)
Review
Oncology
Clemence Riffard, Jean-Luc Teillaud
Summary: CAR-T cells originate from the combination of cellular immunotherapy and molecular engineering, specifically the use of bispecific antibodies to retarget immune effector cells to tumor cells. This approach has shown potent anti-tumor effects and is being further developed to enhance efficacy.
BULLETIN DU CANCER
(2021)
Editorial Material
Medicine, Research & Experimental
Jean-Luc Teillaud
M S-MEDECINE SCIENCES
(2022)
Article
Multidisciplinary Sciences
Benoit Gamain, Carine Brousse, Nathan E. Rainey, Bere K. Diallo, Clara-Eva Paquereau, Alexandra Desrames, Jolita Ceputyte, Jean-Philippe Semblat, Olivier Bertrand, Stephane Gangnard, Jean-Luc Teillaud, Arnaud Chene
Summary: This study proposes a novel immunotherapeutic approach to redirect preexisting antibodies against EBV to target cells, which shows promising results in improving survival and achieving complete cancer remission in animal models.
Article
Hematology
Sahar Kassem, Bere K. Diallo, Nizar El-Murr, Nadege Carrie, Alexandre Tang, Alain Fournier, Helene Bonnevaux, Celine Nicolazzi, Marine Cuisinier, Isabelle Arnould, Sukhvinder S. Sidhu, Jill Corre, Herve Avet-Loiseau, Jean-Luc Teillaud, Helgi van de Velde, Dmitri Wiederschain, Marielle Chiron, Ludovic Martinet, Angela Virone-Oddos
Summary: This study compared the preclinical efficacy of SAR442085, a next-generation anti-CD38 monoclonal antibody (mAb), with first-generation anti-CD38 mAbs daratumumab and isatuximab. SAR442085 demonstrated higher binding affinity and better antibody-dependent cellular cytotoxicity (ADCC) against multiple myeloma (MM) cells compared to daratumumab and isatuximab. In addition, SAR442085 showed increased natural killer (NK) cell activation and degranulation against primary plasma cells, resulting in improved in vivo antitumor efficacy and survival. These findings support the evaluation of SAR442085 in phase I clinical development for patients with relapsed/refractory MM.
Editorial Material
Oncology
Jean-Lu Teillauo, Marie-Caroline Dieu-Nosjean
Summary: Increased plasma cell signatures are found to be predictive of extended overall survival in non-small-cell lung cancer patients treated with a PD-L1 inhibitor, and these cells are associated with the presence of tertiary lymphoid structures.
Article
Gastroenterology & Hepatology
Julia A. Brown, Katherine Z. Sanidad, Serena Lucotti, Carolin M. Lieber, Robert M. Cox, Aparna Ananthanarayanan, Srijani Basu, Justin Chen, Mengrou Shan, Mohammed Amir, Fabian Schmidt, Yiska Weisblum, Michele Cioffi, Tingting Li, Florencia Madorsky Rowdo, M. Laura Martin, Chun-Jun Guo, Costas Lyssiotis, Brian T. Layden, Andrew J. Dannenberg, Paul D. Bieniasz, Benhur Lee, Naohiro Inohara, Irina Matei, Richard K. Plemper, Melody Y. Zeng
Summary: This study reveals the mechanisms by which the gut microbiome protects mammalian hosts from SARS-CoV-2 infection. Short-chain fatty acids reduce viral burden by regulating the viral entry receptor and enhancing adaptive immunity, while also regulating systemic coagulation by limiting megakaryocyte proliferation. These findings have significant implications for understanding the immune and coagulation mechanisms of COVID-19 infection.
Article
Engineering, Biomedical
Chang Liu, Ryan Y. Nguyen, Gabriela A. Pizzurro, Xingjian Zhang, Xiangyu Gong, Alejandro Rossello Martinez, Michael Mak
Summary: 3D in vitro tumor models have been explored for their ability to replicate key features of the tumor microenvironment. We introduced a method to modulate the collagen architecture by disrupting fibrillogenesis and gelation through mechanical agitation, generating collagen scaffolds with thicker and wavy structures. These modified scaffolds promoted tumor cell dissemination and induced differences in cell morphology and migratory behavior.
ACTA BIOMATERIALIA
(2023)
Article
Oncology
Irina Krykbaeva, Kate Bridges, William Damsky, Gabriela A. Pizzurro, Amanda F. Alexander, Meaghan K. McGeary, Koonam Park, Viswanathan Muthusamy, James Eyles, Nadia Luheshi, Noel Turner, Sarah A. Weiss, Kelly Olino, Susan M. Kaech, Harriet M. Kluger, Kathryn Miller-Jensen, Marcus Bosenberg
Summary: Data suggests that combining CD40 activation, CSF1R blockade, and PD-1 inhibition can be effective in overcoming immune checkpoint inhibitor resistance in melanoma. This combination therapy enhances the function of IL12-secreting DCs to recruit activated T cells. The study also identifies a specific subset of DCs as important early-stage effectors of this triple therapy.
CANCER IMMUNOLOGY RESEARCH
(2023)
Article
Oncology
Gabriela A. Pizzurro, Kate Bridges, Xiaodong Jiang, Aurobind Vidyarthi, Kathryn Miller-Jensen, Oscar R. Colegio
Summary: Melanoma, one of the deadliest cancers, is challenging to treat due to the incomplete understanding of its aggressive behavior. High numbers of macrophages in the tumor microenvironment are associated with poor outcomes. This study investigated the origin, evolution, activation profile, and association of macrophages in a melanoma model, providing valuable insights for targeting these cells therapeutically.
Article
Multidisciplinary Sciences
Isabelle Steymans, Luciana M. Pujol-Lereis, Bjorn Brembs, E. Axel Gorostiza
Summary: Our unique character traits define our behavior consistency and individuality, which are not robotic or machine-like repetitive behaviors. Both humans and animals combine personality traits with spontaneity to produce adaptive behavior. In the study of fruit flies, the interaction between individuality and spontaneity explains why group averages are poor predictors of individual choices, even for seemingly stereotype behaviors.
